Terms: = Bone cancer AND RUNX1, PEBP2A2, 861, ENSG00000159216, Q01196, AML1, CBFA2, AMLCR1
432 results:
1. A novel t(X;21)(p11.4;q22.12) translocation adds to the role of BCOR and runx1 in myelodysplastic syndromes and acute myeloid leukemias.
Mavridou E; Lema Fernandez AG; Nardelli C; Pierini V; Quintini M; Arniani S; Di Giacomo D; Crescenzi B; Matteucci C; Sambani C; Mecucci C
Genes Chromosomes Cancer; 2024 Apr; 63(4):e23235. PubMed ID: 38656651
[TBL] [Abstract] [Full Text] [Related]
2. runx1-BMP2 promotes vasculogenic mimicry in laryngeal squamous cell carcinoma via activation of the PI3K-AKT signaling pathway.
Zhu Q; Zhang X; Lu F; Miao S; Zhang C; Liu Z; Gao Z; Qi M; An X; Geng P; Wang S; Ren H; Han F; Zhang R; Zha D
Cell Commun Signal; 2024 Apr; 22(1):227. PubMed ID: 38610001
[TBL] [Abstract] [Full Text] [Related]
3. Sex- and Age-Specific Prevalence of Osteopenia and Osteoporosis: Sampling Survey.
Fan Y; Li Q; Liu Y; Miao J; Zhao T; Cai J; Liu M; Cao J; Xu H; Wei L; Li M; Shen C
JMIR Public Health Surveill; 2024 Apr; 10():e48947. PubMed ID: 38578689
[TBL] [Abstract] [Full Text] [Related]
4. Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders.
Trottier AM; Feurstein S; Godley LA
Best Pract Res Clin Haematol; 2024 Mar; 37(1):101537. PubMed ID: 38490765
[TBL] [Abstract] [Full Text] [Related]
5. Therapeutic Targeting of TIM-4-L with Engineered T Cells for Acute Myeloid Leukemia.
Cieniewicz B; Oliveira E; Saxton M; Torabi D; Bhatta A; Kukutla P; Arballo A; Yang Z; Yu B; Fate M; Ning H; Corey L; Maiti A; Corey D
Clin Cancer Res; 2024 May; 30(9):1878-1888. PubMed ID: 38451195
[TBL] [Abstract] [Full Text] [Related]
6. Diagnostic accuracy of bone SPECT and SPECT/CT imaging in the diagnosis of unilateral condylar hyperplasia: A systematic review and meta-analysis.
Karssemakers LHE; Besseling LMP; Schoonmade LJ; Su N; Nolte JW; Raijmakers PG; Becking AG
J Craniomaxillofac Surg; 2024 Apr; 52(4):447-453. PubMed ID: 38378369
[TBL] [Abstract] [Full Text] [Related]
7. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM).
Mill CP; Fiskus WC; DiNardo CD; Reville P; Davis JA; Birdwell CE; Das K; Hou H; Takahashi K; Flores L; Ruan X; Su X; Loghavi S; Khoury JD; Bhalla KN
Blood Cancer J; 2024 Feb; 14(1):25. PubMed ID: 38316746
[TBL] [Abstract] [Full Text] [Related]
8. runx1/NPM1/H3K4me3 complex contributes to extracellular matrix remodeling via enhancing FOSL2 transcriptional activation in glioblastoma.
Cui X; Huo D; Wang Q; Wang Y; Liu X; Zhao K; You Y; Zhang J; Kang C
Cell Death Dis; 2024 Jan; 15(1):98. PubMed ID: 38286983
[TBL] [Abstract] [Full Text] [Related]
9. Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome.
Arai H; Matsui H; Chi S; Utsu Y; Masuda S; Aotsuka N; Minami Y
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203823
[TBL] [Abstract] [Full Text] [Related]
10. A machine learning radiomics model based on bpMRI to predict bone metastasis in newly diagnosed prostate cancer patients.
Xinyang S; Shuang Z; Tianci S; Xiangyu H; Yangyang W; Mengying D; Jingran Z; Feng Y
Magn Reson Imaging; 2024 Apr; 107():15-23. PubMed ID: 38181835
[TBL] [Abstract] [Full Text] [Related]
11. Genetic Characterization of Pediatric Mixed Phenotype Acute Leukemia (MPAL).
Panagopoulos I; Andersen K; Johannsdottir IMR; Tandsæther MR; Micci F; Heim S
Cancer Genomics Proteomics; 2024; 21(1):1-11. PubMed ID: 38151288
[TBL] [Abstract] [Full Text] [Related]
12. Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals RNA N6-methyladenosine modification associated with prognosis and drug resistance in acute myeloid leukemia.
Li Z; Liu X; Wang L; Zhao H; Wang S; Yu G; Wu D; Chu J; Han J
Front Immunol; 2023; 14():1281687. PubMed ID: 38022588
[TBL] [Abstract] [Full Text] [Related]
13. Diagnostic work-up of hematological malignancies with underlying germline predisposition disorders (GPD).
Kanagal-Shamanna R; Schafernak KT; Calvo KR
Semin Diagn Pathol; 2023 Nov; 40(6):443-456. PubMed ID: 37977953
[TBL] [Abstract] [Full Text] [Related]
14. runx1-R188Q germ line mutation induces inflammation and predisposition to hematologic malignancies in mice.
Ahmad MH; Hegde M; Wong WJ; Mohammadhosseini M; Garrett L; Carrascoso A; Issac N; Ebert B; Silva JC; Pihan G; Zhu LJ; Wolfe SA; Agarwal A; Liu PP; Castilla LH
Blood Adv; 2023 Dec; 7(23):7304-7318. PubMed ID: 37756546
[TBL] [Abstract] [Full Text] [Related]
15. Mechanisms of Secondary Leukemia Development Caused by Treatment with DNA Topoisomerase Inhibitors.
Lomov NA; Viushkov VS; Rubtsov MA
Biochemistry (Mosc); 2023 Jul; 88(7):892-911. PubMed ID: 37751862
[TBL] [Abstract] [Full Text] [Related]
16. Natural history study of patients with familial platelet disorder with associated myeloid malignancy.
Cunningham L; Merguerian M; Calvo KR; Davis J; Deuitch NT; Dulau-Florea A; Patel N; Yu K; Sacco K; Bhattacharya S; Passi M; Ozkaya N; De Leon S; Chong S; Craft K; Diemer J; Bresciani E; O'Brien K; Andrews EJ; Park N; Hathaway L; Cowen EW; Heller T; Ryan K; Barochia A; Nghiem K; Niemela J; Rosenzweig S; Young DJ; Frischmeyer-Guerrerio PA; Braylan R; Liu PP
Blood; 2023 Dec; 142(25):2146-2158. PubMed ID: 37738626
[TBL] [Abstract] [Full Text] [Related]
17. U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity.
Badar T; Vanegas YAM; Nanaa A; Foran JM; Al-Kali A; Mangaonkar A; Murthy H; Alkhateeb HB; Viswanatha D; He R; Shah M; Yi CA; Litzow MR; Gangat N; Tefferi A; Patnaik MM
Blood Cancer J; 2023 Sep; 13(1):149. PubMed ID: 37735430
[TBL] [Abstract] [Full Text] [Related]
18. Development and validation of a web-based artificial intelligence prediction model to assess massive intraoperative blood loss for metastatic spinal disease using machine learning techniques.
Shi X; Cui Y; Wang S; Pan Y; Wang B; Lei M
Spine J; 2024 Jan; 24(1):146-160. PubMed ID: 37704048
[TBL] [Abstract] [Full Text] [Related]
19. Genome-wide transcription factor-binding maps reveal cell-specific changes in the regulatory architecture of human HSPCs.
Subramanian S; Thoms JAI; Huang Y; Cornejo-Páramo P; Koch FC; Jacquelin S; Shen S; Song E; Joshi S; Brownlee C; Woll PS; Chacon-Fajardo D; Beck D; Curtis DJ; Yehson K; Antonenas V; O'Brien T; Trickett A; Powell JA; Lewis ID; Pitson SM; Gandhi MK; Lane SW; Vafaee F; Wong ES; Göttgens B; Alinejad-Rokny H; Wong JWH; Pimanda JE
Blood; 2023 Oct; 142(17):1448-1462. PubMed ID: 37595278
[TBL] [Abstract] [Full Text] [Related]
20. Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.
Tan CR; Derkach A; Nemirovsky D; Ciardiello A; Diamond B; Hultcrantz M; Hassoun H; Mailankody S; Shah U; Maclachlan K; Patel D; Lahoud OB; Landau HJ; Chung DJ; Shah GL; Scordo M; Giralt SA; Lesokhin A; Usmani SZ; Landgren O; Korde N
Blood Cancer J; 2023 Jul; 13(1):112. PubMed ID: 37491332
[TBL] [Abstract] [Full Text] [Related]
[Next]
